FDAnews
www.fdanews.com/articles/73411-encysive-pharmaceuticals-to-retain-european-rights-to-thelin

Encysive Pharmaceuticals to Retain European Rights to Thelin

June 16, 2005

Encysive Pharmaceuticals has announced plans to market Thelin (sitaxsentan sodium) directly in Europe. Thelin, an oral, once daily, highly selective endothelin receptor antagonist, is currently being evaluated by the U.S. Food and Drug Administration (FDA) as a new treatment for pulmonary arterial hypertension (PAH). "Following the positive results of our second pivotal Phase III study, STRIDE-2, and after comprehensive evaluation by management, the board of directors has concluded that the company will market directly in Europe," commented John M. Pietruski, chairman of the board of Encysive Pharmaceuticals.

()a href="http://www.biospace.com/news_story.cfm?StoryID=20368020&full=1" target="_blank">BioSpace